Semaglutide is the most extensively studied compound in the GLP-1 class, and the
human evidence base for it is unusually large. This monograph summarizes the
pharmacology and the trial record.
Chemical identity & structure.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist — a synthetic
analog of the human incretin hormone GLP-1. Its structure is engineered for
durability: an amino-acid substitution at position 8 (alpha-aminoisobutyric acid,
"Aib") blocks degradation by the enzyme DPP-4, and a C18 fatty-diacid chain
attached via a linker promotes reversible binding to albumin in the bloodstream.
Together these modifications extend the half-life to roughly 7 days.
Mechanism of action.
Semaglutide activates the GLP-1 receptor. The downstream effects relevant to
metabolic research are: glucose-dependent stimulation of insulin secretion,
suppression of glucagon, slowing of gastric emptying, and central effects on
appetite and satiety signaling via GLP-1 receptors in the hypothalamus and
hindbrain. The "glucose-dependent" qualifier matters — insulin release is
amplified only when glucose is elevated, which is relevant to the class's
hypoglycemia profile.
Key research findings.
In the SUSTAIN program (type 2 diabetes), semaglutide improved glycemic control
and produced weight loss as a secondary outcome. The STEP program studied
semaglutide specifically for weight management at higher doses and documented
substantial sustained weight loss. The SELECT trial reported a
reduction in major adverse cardiovascular events in a population with
established cardiovascular disease and overweight/obesity. The FLOW trial
examined kidney outcomes.
The research / citation base.
Semaglutide is approved by the FDA and other regulators for type 2 diabetes
(Ozempic, Rybelsus) and for chronic weight management (Wegovy). The trial
program (SUSTAIN, PIONEER, STEP, SELECT, FLOW) is large and published in major
peer-reviewed journals. This is one of the best-evidenced compounds in the
entire peptide space.
Human clinical trial data
In the STEP 1 phase 3 trial by Wilding and colleagues (2021), 1961 adults with overweight or obesity without diabetes were randomly assigned to 68 weeks of treatment with semaglutide or placebo, plus lifestyle intervention (PubMed).
Quality & sourcing notes.
Counterfeit and underdosed semaglutide is a documented, serious problem in the
research-grade supply chain. A credible COA should confirm identity by mass
spectrometry and purity by HPLC, and should be batch-specific. Peptide mass for
semaglutide is approximately 4114 Da — a COA reporting a materially different
mass is a red flag.
*Research-use note: This is an educational summary of published research.
Semaglutide is a prescription drug; this monograph is research context only and
is not medical advice.*